141 results about "Neutralizing epitope" patented technology

A method for the rational design and preparation of vaccines based on HIV envelope polypeptides is described. In one embodiment, the method for making an HIV gp120 subunit vaccine for a geographic region comprises determining neutralizing epitopes in the V2 and/or C4 domains of gp120 of HIV isolates from the geographic region and selecting an HIV strain having gp120 a neutralizing epitope in the V2 or C4 domain which is common among isolates in the geographic region. In a preferred embodiment of the method, neutralizing epitopes for the V2, V3, and C4 domains of gp120 are determined. At least two HIV isolates having different neutralizing epitopes in the V2, V3, or C4 domain are selected and used to make the vaccine. The invention also provides a multivalent HIV gp120 subunit vaccine.

Compositions, kits and methods for boosting, or for priming and boosting, high titer broadly neutralizing cross-clade antibody responses focused on single HIV-1 neutralizing epitopes are disclosed. gp120 DNA plasmids comprising HIV env genes are used to prime the antibody response. Primed subjects are immunized with recombinant fusion proteins that comprise a “carrier” protein fusion partner, preferably a truncated form of the MuLV gp70 Env protein, and a desired HIV neutralizing epitopes. Preferred epitopes are epitopes of V3 from one or more HIV clades. Immune sera from such immunized subjects neutralized primary isolates from virus strains heterologous to those from which the immunogens were constructed. Neutralizing activity was primarily due to V3-specific antibodies and cross-clade neutralizing Abs were present. This approach results in more potent and broader neutralizing antibody levels, a result of “immunofocusing” the humoral immune response on neutralizing epitopes such as V3.

The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.

This disclosure provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.

This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.

The invention relates to a neutralizing epitope peptide (or a variant thereof) from varicella-zoster virus virus (VZV) gE protein, a recombinant protein containing the neutralizing epitope peptide (or the variant thereof) and a carrier protein, and applications of the neutralizing epitope peptide (or a variant thereof) and the recombinant protein, and also relates to an antibody aiming to the neutralizing epitope peptide, a cell strain producing the antibody, and the applications thereof, and also relates to a vaccine containing the neutralizing epitope peptide and the recombinant protein, a medicine composition including the antibody, and the applications thereof, e.g., the application for preventing and/or treating VZV infection or one or more diseases and symptoms related to the infection.

The invention provides new, specific antigenic peptides from the protein GDF8. The invention also provides fusion proteins comprising the new peptides, immunogens and vaccines based on the new peptides and/or fusion proteins, antibodies that specifically bind to the new peptides of GDF8, and methods of treating animals in order to modulate the activity of GDF8, employing vaccines or antibodies according to the invention.

This invention provides antibodies that specifically bind to botulinum neurotoxin type A (BoNT/A) and/or botulinum neurotoxin type B (BoNT/B) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism. Also included in the invention are diagnostic and therapeutic assays directed to botulinum neurotoxins.

The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat asthma, bronchial hyperresponsiveness, atopic allergy, and other related disorders. Particularly disclosed are recombinant antibodies derived from three murine anti-human IL-9 antibodies identified infra as MH9A3, MH9D1, and MH9L1.

The present invention is directed to self-folding, soluble, stable RSV G and F polypeptides that contain a neutralizing epitope. Fusion proteins and immunogenic conjugates containing the RSV G and F polypeptides, along with recombinant transgenes and vectors, and host cells suitable for expression of such genetic constructs are also disclosed. Use of the RSV G and F polypeptides, fusion proteins, immunogenic conjugates, or a pharmaceutical composition containing the same, is contemplated for inducing a protective immune response against RSV.

The invention, which belongs to the technical field of vaccines, particularly relates to an African swine fever neutralizing epitope subunit vaccine that is mainly composed of African swine fever neutralizing epitope fusion protein. The African swine fever neutralizing epitope fusion protein mainly comprises a B cell neutralizing epitope peptide fragment including at least one neutralizing epitopepeptide of p72 protein, at least one neutralizing epitope peptide of p54 protein and at least one neutralizing epitope peptide of p30 protein. With the African swine fever neutralizing epitope fusionprotein, the risk of accelerating virus infection possibly caused by non-neutralizing antibodies can be effectively eliminated and the immune safety of the fusion protein can be effectively improved.Besides, when the African swine fever neutralizing epitope fusion protein is used for immunizing pigs, the antibody level obviously higher than that of a control group can be generated after one immunization.

The invention discloses a foot-and-mouth disease virus (FMDV) resistant monoclonal antibody and an identified epitope and application thereof, and belongs to the field of prevention and control of the FMDV. The microbial collection number of a hybridoma cell line, which can secrete the neutralizing monoclonal antibody resisting to Asia-1 FMDV, is CGMCC No.2692; and the microbial collection number of the hybridoma cell line, which can secrete the neutralizing monoclonal antibody resisting to O-type FMDV, is CGMCC No.2691. The invention also discloses amino acid sequences of a conformational neutralizing epitope of the Asia-1 FMDV VP1 protein and a linear neutralizing epitope of the O-type FMDV VP1 protein which are identified by the two monoclonal antibodies respectively. In-vitro neutralization tests and in-vivo animal protection tests show that both the two monoclonal antibodies have excellent passive immunity effect, can be applied to emergency prevention of the FMDV and have excellent immunity effect on the passive immunity of the FMDV.

The invention relates to an EV71 virus neutralization epitope detection kit or a reagent and a preparation method thereof. Particularly, the invention performs quantitative detection on EV71 virus antigen by adopting an HD6 monoclonal antibody with spectral activity. The kit or the reagent has the advantages of easy operation, high sensitivity and the like.

The invention discloses a PEDV S gene major antigen epitope serial connection recombination gene, and a preparation method and an application thereof, and belongs to the field of a PEDV S protein major neutralizing epitope region efficient expression method. The PEDV S gene major antigen epitope serial connection recombination gene is obtained through connecting three major antigen epitopes of a PEDV S gene in series; every two major antigen epitopes are connected through a flexible amino acid base sequence; the name is S123; and the sequence of the base sequence is shown as SEQ ID NO:1. The recombination gene contains most PEDV antigen epitopes; the selected fragments avoid a high-variation region; the expression quantity is efficient and stable; the immunogenicity is high; when the application of PEDV S gene major antigen epitope serial connection recombination protein to a PEDV indirect ELISA detection kit is used, the PEDV can be fast diagnosed; and the swinery neutralization protection can be well monitored and evaluated.

The invention provides a hemagglutinin (HA) protein neutralizing epitope mimic peptide of H5 subtype avian influenza viruses, a conserved derivative or active fragment or mutant sequence thereof, related coding sequence thereof and the use of the mimic peptide or the conserved derivative or active fragment or mutant sequence thereof in prevention and diagnosis.